Cellebrite Shifts Incorporation to U.S. Amid Strategic Realignment

Less than two years after its Israeli CEO Yossi Carmil departed, Cellebrite announced it is canceling its Israeli registration and will reincorporate as an American company. The digital intelligence firm's board has approved a corporate restructuring that will establish a new U.S. parent company. This move, uncommon for a mature company, involves transferring its place of incorporation and likely its intellectual property from Israel to the United States.

Cellebrite representatives stated that operations in Israel will continue as usual, with no layoffs anticipated. The company expects the reincorporation process to be finalized by the first half of 2027, pending shareholder and regulatory approvals. Cellebrite is currently traded on the Nasdaq stock exchange with a valuation of approximately $3 billion.

Ironically, Carmil, who led the company for most of his two decades there, had previously warned that "relocation is the biggest threat to Israeli high-tech." Cellebrite develops digital investigation and intelligence systems for both public and private sectors, and its software has faced scrutiny for alleged misuse in tracking journalists and activists.

The shift to U.S. incorporation is intended to mitigate negative perceptions associated with being an Israeli company and to facilitate securing significant contracts within the U.S. defense sector. New CEO Shiran Ramij, appointed about a month ago, commented that the "redomiciling" is a strategic development that will better position the company for growth in its largest market and with international government clients. He also believes it will enhance Cellebrite's appeal to a broader investor base by enabling inclusion in major indices.